Management of abemaciclib associated adverse events in patients with hormone receptor positive (HR+), HER2- advanced breast cancer: Analysis of the MONARCH trials

H. S. Rugo; S. M. Tolaney; J. Huober; M. Toi; V. André; S. Barriga; T. Forrester; G. W. Sledge; M. P. Goetz

doi:10.1093/annonc/mdy272.329

Management of abemaciclib associated adverse events in patients with hormone receptor positive (HR+), HER2- advanced breast cancer: Analysis of the MONARCH trials

H. S. Rugo, S. M. Tolaney, J. Huober, M. Toi, V. André, S. Barriga, T. Forrester, G. W. Sledge, M. P. Goetz

Medical Oncology

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	viii110-viii111
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy272.329
State	Published - Oct 1 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy272.329

Cite this

Rugo, H. S., Tolaney, S. M., Huober, J., Toi, M., André, V., Barriga, S., Forrester, T., Sledge, G. W., & Goetz, M. P. (2018). Management of abemaciclib associated adverse events in patients with hormone receptor positive (HR+), HER2- advanced breast cancer: Analysis of the MONARCH trials. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii110-viii111. https://doi.org/10.1093/annonc/mdy272.329

Management of abemaciclib associated adverse events in patients with hormone receptor positive (HR+), HER2- advanced breast cancer : Analysis of the MONARCH trials. / Rugo, H. S.; Tolaney, S. M.; Huober, J. et al.

In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii110-viii111.

Research output: Contribution to journal › Article › peer-review

Rugo, HS, Tolaney, SM, Huober, J, Toi, M, André, V, Barriga, S, Forrester, T, Sledge, GW & Goetz, MP 2018, 'Management of abemaciclib associated adverse events in patients with hormone receptor positive (HR+), HER2- advanced breast cancer: Analysis of the MONARCH trials', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii110-viii111. https://doi.org/10.1093/annonc/mdy272.329

Rugo HS, Tolaney SM, Huober J, Toi M, André V, Barriga S et al. Management of abemaciclib associated adverse events in patients with hormone receptor positive (HR+), HER2- advanced breast cancer: Analysis of the MONARCH trials. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii110-viii111. doi: 10.1093/annonc/mdy272.329

@article{0403cb94ca1e42c8a2eaf5ede20cc93d,

title = "Management of abemaciclib associated adverse events in patients with hormone receptor positive (HR+), HER2- advanced breast cancer: Analysis of the MONARCH trials",

author = "Rugo, {H. S.} and Tolaney, {S. M.} and J. Huober and M. Toi and V. Andr{\'e} and S. Barriga and T. Forrester and Sledge, {G. W.} and Goetz, {M. P.}",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy272.329",

language = "English (US)",

volume = "29",

pages = "viii110--viii111",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Management of abemaciclib associated adverse events in patients with hormone receptor positive (HR+), HER2- advanced breast cancer

T2 - Analysis of the MONARCH trials

AU - Rugo, H. S.

AU - Tolaney, S. M.

AU - Huober, J.

AU - Toi, M.

AU - André, V.

AU - Barriga, S.

AU - Forrester, T.

AU - Sledge, G. W.

AU - Goetz, M. P.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85081530515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081530515&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy272.329

DO - 10.1093/annonc/mdy272.329

M3 - Article

C2 - 32136124

VL - 29

SP - viii110-viii111

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

ER -

Management of abemaciclib associated adverse events in patients with hormone receptor positive (HR+), HER2- advanced breast cancer: Analysis of the MONARCH trials

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this